Andrea Necchi, Head of Genitourinary Medical Oncology at Ospedale San Raffaele, shared on X:
“This is an important release in Journal of Clinical Oncology in conjunction with ESMO26 DASL HiCaP trial. Identifying pts who benefit the most from intensified treatment is a work in progress.
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.”
Title: ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer
Authors: Scott Williams, Christopher J. Sweeney, Hayley Thomas, Blossom Mak, Alison Zhang, Tee Sin Lim, Chakiath Jose, Jarad Martin, Nitya Patanjali, David Pryor, Phuong Tran, Stephen Mangar, Alina M. Mihai, Carys Thomas, Simon Gampenrieder, Sonia Yip, Leanna Cheung, Sandra Lee, Annabelle Goodwin, Annette Haworth, Anna Walsh, Paul J. Kelly, Simon Hughes, Andrew Martin, Ray McDermott, Martin Stockler, Ian D. Davis, Paul L. Nguyen
You can also read:
